TY - JOUR
T1 - J-LEAPS peptide and LEAPS dendritic cell vaccines
AU - Rosenthal, Ken S.
AU - Taylor, Patricia
AU - Zimmerman, Daniel H.
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/3
Y1 - 2012/3
N2 - The J-LEAPS vaccines contain a peptide from β-2-microglobulin covalently attached to disease-related peptides of 8-30 amino acids which contain a T cell epitope. The J-LEAPS vaccines can initiate a protective Th1 immune response or modulate an ongoing Th17 autoimmune response to the peptide. J-LEAPS vaccines activate and direct the nature of the subsequent immune response by promoting the maturation of precursor cells into a unique type of dendritic cell that produces interleukin 12, but not IL-1 or tumour necrosis factor, and presents the antigenic peptide to T cells. Adoptive transfer of JgD-LEAPS dendritic cells, matured with an anti-HSV-1 vaccine, promoted antigen-specific Th1 protection against lethal challenge with the virus. J-LEAPS peptide immunogens and J-LEAPS dendritic cell vaccines have potential applications for antimicrobial prevention and therapy, treatment of autoimmune diseases, and for cancer immunotherapy.
AB - The J-LEAPS vaccines contain a peptide from β-2-microglobulin covalently attached to disease-related peptides of 8-30 amino acids which contain a T cell epitope. The J-LEAPS vaccines can initiate a protective Th1 immune response or modulate an ongoing Th17 autoimmune response to the peptide. J-LEAPS vaccines activate and direct the nature of the subsequent immune response by promoting the maturation of precursor cells into a unique type of dendritic cell that produces interleukin 12, but not IL-1 or tumour necrosis factor, and presents the antigenic peptide to T cells. Adoptive transfer of JgD-LEAPS dendritic cells, matured with an anti-HSV-1 vaccine, promoted antigen-specific Th1 protection against lethal challenge with the virus. J-LEAPS peptide immunogens and J-LEAPS dendritic cell vaccines have potential applications for antimicrobial prevention and therapy, treatment of autoimmune diseases, and for cancer immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84857209210&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857209210&partnerID=8YFLogxK
U2 - 10.1111/j.1751-7915.2011.00278.x
DO - 10.1111/j.1751-7915.2011.00278.x
M3 - Short survey
C2 - 21895992
AN - SCOPUS:84857209210
VL - 5
SP - 203
EP - 213
JO - Microbial Biotechnology
JF - Microbial Biotechnology
SN - 1751-7907
IS - 2
ER -